Brian Lian
Principal executive officer pay for Brian Lian, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Viking Therapeutics, Inc. (VKTX) FY2021–FY2025
Beat peersTSR 665% vs peer group 25% over FY2021–FY2025
Turnaround$100 invested moved from behind the peer group ($81.71 vs $100.02) to ahead ($624.87 vs $124.75) over FY2021–FY2025
Aligned: paid up as stock roseCAP $2,805,866→$7,500,137 while $100 invested went $81.71→$624.87
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $4.1M | $2.8M |
| FY2022 | $5.4M | $13.3M |
| FY2023 | $12.6M | $36.9M |
| FY2024 | $14.3M | $106.8M |
| FY2025 | $21.3M | $7.5M |
The company's "$100 invested" index ran $81.71 at FY2021 → $624.87 by FY2025 — an annualized return of 66.3%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 66.3%/yr at VKTX ( FY2021–FY2025). See the CEO track-record ranking for context.